Leinco Technologies Acquires QED Biosciences from Genovis
September 3, 2024
Leinco Technologies, a portfolio company backed by Ampersand Capital Partners, has acquired Genovis-owned QED Biosciences to expand its catalog of antibodies, recombinant proteins and IVD raw materials. The deal transfers Genovis' antibody business to Leinco and strengthens Leinco's antibody development and IVD support capabilities for research and diagnostics customers worldwide.
- Buyers
- Leinco Technologies, Ampersand Capital Partners
- Targets
- QED Biosciences
- Sellers
- Genovis
- Platforms
- Leinco Technologies
- Industry
- Biotechnology
- Location
- California, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.